AxoGen Surpasses Expectations in Q2 2026: Strong Revenue Growth and Expanded Market Reach
July 29, 2026 - AxoGen, a leading company in the field of nerve repair and regeneration, has reported a strong second quarter performance for 2026. The company's President and Chief Executive Officer, Michael Dale, highlighted the key highlights from the quarter during a recent conference call.
AxoGen's revenue growth was particularly impressive, with a 23% year-over-year increase in the second quarter to $69.7 million. This growth was driven by strong demand for Avance, the company's flagship product, and continued adoption of its broader product algorithm across all target markets. The breast business showed particular strength, contributing approximately two-thirds of the quarter's growth with a 47% year-over-year increase in revenue.
The company's adjusted net income was $7.3 million for the quarter, while adjusted EBITDA was $8.4 million. AxoGen also ended the period with $113.4 million in cash equivalents, restricted cash, and investments.
AxoGen's strong performance is a testament to the company's strategic plan, which focuses on six key priorities: revenue growth and financial operating leverage, market development, clinical development and regulatory efforts, training and education initiatives, research and development activities, and overall business strategy and performance. The company has consistently exceeded its goals for growing adoption of nerve care by existing surgeons, increasing the numbers of new surgeons, expanding the number of new accounts, and growing patient awareness overall.
The company's sales force productivity continued to exceed expectations, with a meaningful increase in active surgeon count during the quarter. This is an indicator that reflects broader institutional adoption of nerve care. AxoGen's investments in its sales force expansion throughout 2025 and the first half of 2026 are also starting to bear fruit, as those representatives progress through their ramp and approach full productivity consistent with the company's market development model.
Overall, AxoGen's Q2 performance demonstrates the company's continued success in expanding its market reach and delivering strong financial results. As the company looks to the future, it is well-positioned to build on this momentum and continue to drive growth in the nerve repair and regeneration market.
